Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Savings Tool Spotlights Consumer Reports’ “Best Buy” Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

PBM will feature link to Consumer Reports Best Buy Drugs for certain medication classes.
Advertisement

Related Content

Ambien Generics Grab 5 Percent of Insomnia Market In First Week
Ambien Generics Grab 5 Percent of Insomnia Market In First Week
Consumer Reports Rates Prilosec OTC As Best Buy Proton Pump Inhibitor
Consumer Reports Rates Prilosec OTC As Best Buy Proton Pump Inhibitor
Sepracor Sees Sweet Dreams For Lunesta Despite Generic Ambien Next Year
Sepracor Sees Sweet Dreams For Lunesta Despite Generic Ambien Next Year
Medco Analysis Finds Link Between Number of Physicians And Adverse Drug Events
Statin Comparative Studies Needed, Oregon Drug Effectiveness Review Project Suggests
Alzheimer’s Therapies “Best Buys” Named By Consumer Reports
Alzheimer’s Therapies “Best Buys” Named By Consumer Reports

Topics

Advertisement
UsernamePublicRestriction

Register

PS064675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel